Patents by Inventor Amnon Peled
Amnon Peled has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131111Abstract: A composition comprising BL-8040 (SEQ ID NO: 1) is disclosed herein, which may be for use in treating a condition treatable by BL-8040. The composition further comprises at least one compound characterized by a relative retention time of from 0.86 to 0.88 and/or a relative retention time of from 0.71 to 0.73 (wherein a relative retention time of BL-8040 is 1) under conditions described herein.Type: ApplicationFiled: December 13, 2023Publication date: April 25, 2024Applicants: BioLineRx Ltd., Biokine Therapeutics Ltd.Inventors: Efrat HALBFINGER, Amnon PELED, Ella SORANI
-
Publication number: 20240082348Abstract: A composition comprising BL-8040 (SEQ ID NO: 1) is disclosed herein, which may be for use in treating a condition treatable by BL-8040. The composition further comprises at least one compound characterized by a relative retention time of from 0.86 to 0.88 and/or a relative retention time of from 0.71 to 0.73 (wherein a relative retention time of BL-8040 is 1) under conditions described herein.Type: ApplicationFiled: December 29, 2021Publication date: March 14, 2024Applicants: BioLineRx Ltd., Biokine Therapeutics Ltd.Inventors: Efrat HALBFINGER, Amnon PELED, Ella SORANI
-
Publication number: 20240002347Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.Type: ApplicationFiled: September 19, 2023Publication date: January 4, 2024Applicant: AlonBio Ltd.Inventors: Amnon PELED, Michal ABRAHAM KARNI, Orly EIZENBERG
-
Patent number: 11780814Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.Type: GrantFiled: January 27, 2022Date of Patent: October 10, 2023Assignee: AlonBio Ltd.Inventors: Amnon Peled, Michal Abraham Karni, Orly Eizenberg
-
Publication number: 20230242644Abstract: A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.Type: ApplicationFiled: February 14, 2023Publication date: August 3, 2023Applicants: BioLineRx Ltd., Merck Sharp & Dohme Corp.Inventors: Abi VAINSTEIN-HARAS, Ella SORANI, Irit GLIKO-KABIR, Osnat BOHANA-KASHTAN, Amnon PELED
-
Patent number: 11648293Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: May 16, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11642393Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: May 9, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Publication number: 20230133409Abstract: The present invention is directed to a method for treating an IFN-? associated disease or disorder in a subject in need thereof, including administering to the subject a pharmaceutical composition including a therapeutically effective amount of a compound capable of manipulating or modulating PD-L1 signaling or pathway.Type: ApplicationFiled: March 22, 2021Publication date: May 4, 2023Inventors: Amnon PELED, Shira LEVI
-
Patent number: 11638743Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: May 2, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11638742Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: May 2, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11612638Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: March 28, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11607444Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: March 21, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11596666Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: March 7, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11590200Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: February 28, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11559562Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an MO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: January 24, 2023Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11554159Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: January 17, 2023Assignees: Blokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Patent number: 11534478Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.Type: GrantFiled: May 5, 2020Date of Patent: December 27, 2022Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.Inventors: Amnon Peled, Yaron Pereg
-
Publication number: 20220288088Abstract: The present invention provides methods of use for compositions comprising an immunotherapeutic such as chimeric antigen receptor T cells (CAR-T cells), and specifically those that target a tumor antigen cleaved by gamma secretase, in combination with bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; for treating lymphomas.Type: ApplicationFiled: May 17, 2022Publication date: September 15, 2022Applicant: Ayala Pharmaceuticals Inc.Inventors: David SIDRANSKY, Amnon PELED
-
Publication number: 20220144777Abstract: Compounds capable of, or usable in, inducing death of cancer cells and/or modulating a biological activity of a chemokine e.g., cell migration, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or in treating cancer, are provided herein. The compounds are collectively represented by Formulae Ia or Ib: wherein A, B, D, E, G and R1-R5 are as defined in the specification, with one or more of D, E and G, preferably E, is hydroxy.Type: ApplicationFiled: January 27, 2022Publication date: May 12, 2022Applicant: Biokine Therapeutics Ltd.Inventors: Amnon PELED, Michal ABRAHAM KARNI, Orly EIZENBERG
-
Publication number: 20220072087Abstract: A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a peptide set forth in SEQ ID NO: 1 and a chemotherapy comprising irinotecan, fluorouracil (5-FU) and leucovorin (LV), thereby treating the metastatic pancreatic adenocarcinoma, wherein the subject is not subjected to treatment with an anti-PD-1.Type: ApplicationFiled: October 17, 2019Publication date: March 10, 2022Applicants: BioLineRx Ltd., Biokine Therapeutics Ltd.Inventors: Gideon STEIN, Amnon PELED